Policy

How biosimilar policy frameworks differ across major markets and what it means for prescribing

Biosimilar policy frameworks across the EU, UK, US, and adjacent markets differ materially in interchangeability rules, prescriber-substitution practice, and payer-incentive design. The differences shape biosimilar uptake patterns, originator commercial trajectories, and the broader biologic class economics.